Therapeutic Drug Monitoring of Beta-Lactams in Cystic Fibrosis: Unattained Target in Standard Antibiotic Dosing
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu kazuistiky, časopisecké články
Grantová podpora
project MUNI/A/1433/2023
Masarykova Univerzita
FNBr, 65269705
Ministerstvo Vnitra Ceske Republiky
PubMed
40397762
PubMed Central
PMC12422600
DOI
10.1097/ftd.0000000000001340
PII: 00007691-990000000-00353
Knihovny.cz E-zdroje
- Klíčová slova
- cystic fibrosis, meropenem, piperacillin, therapeutic drug monitoring,
- MeSH
- beta-laktamová antibiotika * aplikace a dávkování farmakokinetika MeSH
- cystická fibróza * komplikace MeSH
- lidé MeSH
- meropenem aplikace a dávkování farmakokinetika MeSH
- mladý dospělý MeSH
- monitorování léčiv MeSH
- piperacilin aplikace a dávkování farmakokinetika MeSH
- pseudomonádové infekce * farmakoterapie MeSH
- Pseudomonas aeruginosa MeSH
- Check Tag
- lidé MeSH
- mladý dospělý MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- beta-laktamová antibiotika * MeSH
- meropenem MeSH
- piperacilin MeSH
Acute exacerbations of cystic fibrosis (CF) diminish quality of life and, if inadequately treated, can be life-threatening. The pathophysiological alterations associated with CF result in modified antibiotic pharmacokinetics. Moreover, the viscous mucus in the lungs limits pathogen exposure to drugs, rendering successful antibiotic treatment challenging. A 23-year-old female patient with CF was repeatedly admitted for intravenous antibiotic therapy for acute exacerbation of Pseudomonas aeruginosa infection. In the context of altered pharmacokinetics in CF, therapeutic drug monitoring of meropenem and piperacillin revealed consistently low plasma levels of both drugs. Targeted plasma levels were ultimately achieved through continuous high-dose infusions, based on therapeutic drug monitoring and subsequent dose adjustments.
Department of Clinical Pharmacy Hospital Pharmacy University Hospital Brno Brno Czech Republic
Faculty of Medicine Masaryk University Brno Brno Czech Republic
Zobrazit více v PubMed
Reynolds D, Kollef M. The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update. Drugs. 2021;81:2117–2131. PubMed PMC
Sorgel F, Kinzig M, Labisch C. Cystic Fibrosis Pulmonary Infections: Lessons from Around the World. Birkhauser Verlag; 1996.
Berrino PM, Gatti M, Rinaldi M, et al. Pharmacokinetic/pharmacodynamic target attainment of continuous infusion Piperacillin–Tazobactam or Meropenem and microbiological outcome among urologic patients with documented Gram-Negative infections. Antibiotics. 2023;12:1388. PubMed PMC
Gatti M, Cojutti PG, Pascale R, et al. Assessment of a PK/PD target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented Gram-Negative infections. Antibiotics. 2021;10:1311. PubMed PMC
Maguigan KL, Al-Shaer MH, Peloquin CA. Beta-lactams dosing in critically ill patients with Gram-Negative bacterial infections: a PK/PD approach. Antibiotics. 2021;10:1154. PubMed PMC
Drwiega EN, Rodvold KA. Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update. Clin Pharmacokinet. 2022;61:17–46. PubMed PMC
The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 14.0; 2024. Available at: http://www.eucast.org/clinical_breakpoints/
Stašek J, Keller F, Kočí V, et al. Update on therapeutic drug monitoring of beta-lactam antibiotics in critically ill patients—a narrative review. Antibiotics. 2023;12:568. PubMed PMC
Drew RH. Dosing and Administration of Parenteral Aminoglycosides. UpToDate © 2025 Wolters Kluwer. (Topic 475 Version 36.0, updated: Nov 22, 2024).
Cusumano JA, Klinker KP, Huttner A, et al. Towards precision medicine: therapeutic drug monitoring–guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity. Am J Health Syst Pharm. 2020;77:1104–1112. PubMed
Quinton MC, Bodeau S, Kontar L, et al. Neurotoxic concentration of piperacillin during continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2017;61:e00654-17. PubMed PMC
Akkerman-Nijland AM, Akkerman OW, Grasmeijer F, et al. The pharmacokinetics of antibiotics in cystic fibrosis. Expert Opin Drug Metab Toxicol. 2021;17:53–68. PubMed
Castagnola E, Cangemi G, Mesini A, et al. Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review. Int J Antimicrob Agents. 2021;58:106381. PubMed
Katz JB, Shah P, Trillo CA, et al. Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function. Respir Med. 2023;212:107237. PubMed
Magréault S, Roy C, Launay M, et al. Pharmacokinetic and pharmacodynamic optimization of antibiotic therapy in cystic fibrosis patients: current evidences, gaps in knowledge and future directions. Clin Pharmacokinet. 2021;60:409–445. PubMed
